Evans Syndrome following T Cell-repleted Unrelated Bone Marrow Transplantation for Myelodysplastic Syndrome: Successful Response to High-dose Corticosteroid

Young-Ho Lee, M.D.¹, Young-Dae Kim, M.D.² and Yeong-Myung Kim, M.D.³

Department of Pediatrics, ¹Hanyang University Medical Center, Seoul, ²Inje University Paik Hospital, Seoul, ³Dong-A University Medical Center, Busan, Korea

Evans syndrome after hematopoietic stem cell transplantation rarely occurs and this condition is refractory to treatment, particularly in childhood. We experienced a case of Evans syndrome following unmanipulated unrelated bone marrow transplantation. Evans syndrome developed at early post-transplantation period (day +42) and it responded very well to high-dose corticosteroid. Autoimmune cytopenia should be considered for post-engraftment cytopenias and high-dose corticosteroid therapy might be considered as a treatment of the early onset type of autoimmune cytopenia that can occur after hematopoietic stem cell transplantation. (*Korean J Hematol 2006;41:204-207.*)

**Key Words:** Evans syndrome, T cell repleted bone marrow transplantation, High-dose corticosteroid

**INTRODUCTION**

Although autoimmune cytopenia is infrequent complication following hematopoietic stem cell transplantation (HSCT), it has been reported after allogeneic¹-⁴ as well as autologous stem cell transplantation.⁵,⁶ Autoimmune cytopenia following HSCT variably responded to immunoglobulin or other immunosuppressive treatment and also associated with a high mortality rate.

Evans syndrome is direct Coombs’ test positive hemolytic anemia with immune thrombocytopenic purpura,⁷-¹⁰ which is rarely reported in children, particularly, who received HSCT.¹¹,¹² We describe here an 11 years old girl with Evans syndrome following unrelated bone marrow transplantation (BMT), which promptly responded to high-dose steroid therapy.

**CASE REPORT**

An 11-year-old girl presented with pallor and petechiae on the trunk. CBC revealed a hemoglobin concentration (Hb) 7.6g/dL, white blood cell count (WBC) 4,690/μL, platelet count 13,000/μL: and bone marrow aspiration and biopsy findings were consistent with myelodysplastic syndrome (refractory anemia). The cytogenetic study revealed normal female chromosome. She received only intermittent transfusions of packed red cells or platelets, until when underwent unrelated
BMT from Japan Marrow Donor Program. The donor was same with this child in DNA based-HLA type, blood type (Rh+, B) and sex.

Pretransplant conditioning was done with busulfan (0.8mg/kg, i.v. every 6 hours for 4 days, total dose 12.8mg/kg) and cyclophosphamide (60 mg/kg/day, i.v. for 2 days, total dose 120mg/kg). GVHD prophylaxis consisted of tacrolimus (0.05 mg/kg/day) and methotrexate (10mg/m², i.v.) Prophylaxis against venoocclusive disease used lipoprostaglandin E₁ (lipoprostaglandin E₁, 1 μg/kg/day, i.v.). Granulocyte colony-stimulating factor (5 μg/kg/day, i.v.) was used from day +5 after transplant until the absolute neutrophil count exceeded 1,000/μL.

She was engrafted promptly on day +10 for neutrophil and on day +18 for platelet. She experienced mild hemorrhagic cystitis and grade I skin GVHD, which easily controlled with supportive therapy. Chimerism study with PCR (polymerase chain reaction) of STR (short tandem repeat) on day +21 showed 100% donor hematopoiesis. Bone marrow biopsy was done on day +35, which revealed trilineage engraftment with 40% of cellularity.

Until 42 days after transplant, platelet count was steadily increased to 90,000/μL and Hb level was maintained above 10g/dL. Since then, her hemoglobin level was decreased to 7.6g/dL and platelet count below 20,000/μL. For evaluating post-engraftment cytopenia, we repeated bone marrow study and chimerism study which revealed persistent trilineage engraftment with 100% donor hematopoiesis. Tests for bacterial and viral infections (cytomegalovirus, Epstein-Barr virus, herpes virus) were negative. We also performed the tests for hemolysis, which showed increased level of indirect bilirubin (2.5mg/dL), serum LDH (532 U/L), and corrected reticulocyte count (1.6%). The direct Coombs test and platelet associated antibody were positive, but indirect Coombs test and antiplatelet antibody were negative.

High-dose methylprednisone (30mg/kg/day) was administered intravenously for 3 days from day +61 with maintaining therapeutic tacrolimus level. Within 1 week, her platelet count and hemoglobin concentrates stabilized without transfusion and steadily increased. Although the hemoglobin level normalized by day +66, the platelet counts transiently decreased again by day +98 due to herpes zoster infection and increased to normal level by day +126. The direct Coombs test was converted to negative on day +115 (Fig. 1). She continues the evidence of trilineage hematopoiesis with obviously well conditions.

**DISCUSSION**

Autoimmune cytopenia, particularly autoimmune hemolytic anemia (AIHA) is uncommon
complication after hematopoietic stem cell transplantation of allogeneic or autologous source. Although the incidence of AIHA after allogeneic BMT was estimated at 3%, the increased incidence (15.5%) of AIHA after T cell depleted stem cell transplantation was noted.4)

Evans syndrome also has been rarely described in recipients who underwent allogeneic BMT, unrelated cord blood stem cell transplantation, or autologous BMT. They also received potent T cell suppression with antithymocyte globulin (ATG) and/or OKT3 as part of the conditioning regimen. Dovat et al reported the 8-month-old male with Evans syndrome which developed on 4 months after cord blood stem cell transplantation. He received multiple courses of intravenous immunoglobulin, anti-Rh D immunoglobulin, a pulse of high-dose corticosteroids and cyclosporine with only some improvement of hemolytic anemia, but no improvement of the thrombocytopenia. Addition of vincristine resulted in long-term resolution of thrombocytopenia and anemia. Drobyski et al also reported the 27-year-old female who experienced Evans syndrome after unrelated bone marrow transplantation and showed partial response to various kinds of treatment such as steroids, immunoglobulin, ATG, danazole/vincristine, and plasma pheresis.

Although there are controversies regarding the concomitance with the onset of hemolysis and leukemic relapse, in many instances, the onset of hemolysis coincided with the cessation of immunosuppressive therapy. These evidences probably reflect increased defective regulation of autoreactive B cells as a consequence of T cell defects and consequently an increase in autoimmune disorders. Although our patient received T cell repleted bone marrow from unrelated donor following conditioning regimen with busulfan and cyclophosphamide without ATG or OKT3, she developed thrombocytopenia and Coombs’ positive hemolytic anemia 42 days after unrelated BMT. She was on immunosuppressive treatment with complete chimerism of donor type, and responded very well to high-dose methylprednisone. She experienced several times of viral infections following this event of Evans syndrome, which suggests still noted impairment of T cell function although we could not perform the immunologic studies.

Although immune hemolysis due to ABO/Rh mismatch occurs within first 6 weeks following BMT, the cases of autoimmune hemolytic anemia arise longer than 8 weeks post-BMT. Chen et al reported autoimmune hemolytic anemia following BMT as two distinct groups: an early onset group associated with cold antibody occurring between 2 and 8 months and a late onset group associated with warm antibody occurring between 6 and 18 months after BMT. Our patient who received ABO/Rh matched marrow developed hemolysis on day +42 after BMT, which may reflect autoreactive donor B cells might begin Ig M production and destroy red cells. The response to treatment was also rapid and complete because, even we are not sure, the cold antibody in the early onset group may be clinically benign.

In our case, although we could not find the previously reported etiologies such as concurrent viral infections, the use of T-cell depleted marrow or ATG/OKT3 as a part of conditioning regimen, and the reduction of immunosuppressive drugs, we experienced the early onset type of Evans syndrome promptly responded to high-dose corticosteroid.

요 약

조혈모세포이식 이후에 발생하는 Evans 증후군은 아주 드물게 발생하며, 치료에 반응을 잘하지 않는다. 저자들은 T세포를 제거하지 않은 비혈연 골수이식 이후에 발생한 Evans 증후군은 우수한 예로, 이식 후 42일째 발생하였으며 고용량의 스테로이드 치료에 잘 반응하였다. 따라서 조혈모세포이식 후 생장이 된 이후에 발생하는 혈구감소증의 경우에는 자가면역성 혈구감소증도 의심해야 하겠 다.
REFERENCES


